Table 6.

Summary of efficacy according to EGFR sensitizing mutation (common or rare) and common sensitizing EGFR mutation type (exon 19 deletion or L858R) and first-line treatment (EGFR TKI or chemotherapy) used in patients carrying common sensitizing EGFR mutations

	EGFR sensitizing mutation (n = 132) mutation (n = 131)		Common sensitizing EGFR mutation (n = 112)
			Type of mutation		First-line treatment
Endpoint	Common	Rare	Del 19	L858R	TKI	CT
Evaluable	112	20	82	30	96	16
Response, n (%)
CR	3 (3.1)	0 (0.0)	2 (2.9)	1 (3.6)	3 (3.1)	1 (6.3)
PR	48 (50.0)	2 (12.5)	35 (51.5)	13 (46.4)	48 (50.0)	2 (12.5)
SD	38 (39.6)	8 (50.0)	27 (39.7)	11 (39.3)	38 (39.6)	11 (68.8)
PD	7 (7.3)	6 (37.5)	4 (5.9)	3 (10.7)	7 (7.3)	2 (12.5)
ORR, n (%)	51 (53.1)	2 (12.5)	37 (54.4)	14 (50.0)	51 (53.1)	3 (18.8)
95% CI	42.7–63.4	1.6–38.4	41.9–66.5	30.6–69.4	42.7–63.4	4.0–45.6
DCR, n (%)	89 (92.7)	10 (62.5)	64 (94.1)	25 (89.3)	89 (92.7)	14 (87.5)
95% CI	85.6–97.0	35.4–84.8	85.6–98.4	71.8–97.7	85.6–97.0	61.7–98.4

CI Confidence interval, CR Complete response, DCR Disease control rate, ORR Overall response rate, PR Partial response, PD Progressive disease, SD Stable disease